Triptocalline A is primarily studied for its potential anti-inflammatory and immunomodulatory properties. It has shown activity in suppressing pro-inflammatory cytokines, making it a candidate for research in autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. Additionally, it exhibits neuroprotective effects in preclinical models, suggesting possible application in neurodegenerative disorders like Alzheimer’s and Parkinson’s disease. Its ability to cross the blood-brain barrier enhances its suitability for central nervous system-targeted therapies. Ongoing studies are also exploring its role in cancer treatment due to its capacity to induce apoptosis in certain tumor cell lines. Most applications remain in the experimental stage, with emphasis on developing derivatives to improve stability and bioavailability.